Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | B3GNT2 | Q9NY97 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30279787 | 1.00 | MAOB (0.53) | MAOBLMNAPGRHTR1ADRD2 | |
| SCHEMBL16174315 | 0.87 | LMNA (0.51) | MAOBLMNAPGRHTR1ADRD2 | |
| SCHEMBL12727792 | 0.85 | MAOB (0.55) | MAOBLMNAPGRHTR1ADRD2 | |
| SCHEMBL14582468 | 0.83 | MAOB (0.53) | MAOBLMNAPGRHTR1ADRD2 | |
| SCHEMBL3923772 | 0.83 | MAOB (0.53) | MAOBLMNAPGRHTR1ADRD2 | |
| SCHEMBL22493206 | 0.83 | MAOB (0.50) | MAOBLMNAPGRHTR1ADRD2 | |
| SCHEMBL12881773 | 0.82 | MAOB (0.52) | MAOBLMNAPGRHTR1ADRD2 | |
| SCHEMBL20529142 | 0.81 | PGR (0.45) | MAOBLMNAPGRDAOBRD4 | |
| SCHEMBL20529212 | 0.81 | CYP1A2 (0.57) | MAOBLMNAPGRDAOBRD4 | |
| SCHEMBL31282254 | 0.81 | MAOB (0.51) | MAOBLMNAPGRHTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | Kynan Duke IP, LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2023-05-25 | — | — | US | disclosed |
| CN-115485259-A | Substituted hydroxystilbene compounds and derivatives, synthesis and use thereof | 凯楠公爵IP有限责任公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-3606921-B1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021127743-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | Kynan Duke IP, LLC (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | INVENTIVA (FR) | 2020-04-16 | — | — | US | disclosed |
| EP-3606921-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | Inventiva (FR) | 2020-02-12 | — | — | EP | disclosed |
| CN-110709396-A | Novel compound inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma | 伊文蒂瓦公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018185266-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA. | INVENTIVA (FR) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459883-B2 | Substituted hydroxystilbene compounds and derivatives synthesis and uses thereof | CYP8B1, HSD11B1, HSD11B2 | MAOB 145/4885LMNA 636/4885PGR 1632/4885 |
| US-20200115353-A1 | NEW COMPOUNDS INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF MALIGNANT MESOTHELIOMA | YAP1, TEAD2, TEAD1 | MAOB 3985/4885LMNA 1393/4885PGR 4402/4885 |
| US-20230159421-A1 | SUBSTITUTED HYDROXYSTILBENE COMPOUNDS AND DERIVATIVES SYNTHESIS AND USES THEREOF | CYP8B1, HSD11B1, HSD11B2 | MAOB 145/4885LMNA 636/4885PGR 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.